+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy



De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy



American Journal of Kidney Diseases 41(2): 471-479



Thrombotic microangiopathy (TMA) is a well-recognized and serious complication of renal transplantation, affecting 3% to 14% of patients administered calcineurin-inhibitor-based immunosuppression. We reviewed 1,219 biopsy reports of 742 kidney and kidney-pancreas transplants performed during 15 years at our center and found 21 biopsy-confirmed cases of TMA. On presentation, the majority (62%) had systemic TMA with manifest hemolysis and thrombocytopenia, whereas a subset had TMA localized only to the graft (38%). There were no statistically significant differences in sex, type of transplant, age, race, or type of immunosuppression. Patients with systemic TMA were more likely to be treated with plasma exchange (38% versus 13%; P < 0.05), more often required dialysis therapy (54% versus 0%; P = 0.01), and had a greater rate of graft loss (38% versus 0%; P < 0.05). No patient with the localized variant had TMA-related graft loss. Patients with localized TMA often responded to reduction, conversion, or temporary discontinuation of calcineurin-inhibitor-based immunosuppression therapy and did not routinely require plasma exchange for graft salvage. We compare our findings with the literature regarding the prognosis of TMA. Classifying patients with post-renal transplantation TMA into those with localized and systemic disease is clinically useful because each group has distinct characteristics and clinical courses.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 045707059

Download citation: RISBibTeXText

PMID: 12552512

DOI: 10.1053/ajkd.2003.50058


Related references

De novo thrombotic microangiopathy in renal transplant recipients A comparison of hemolytic uremic syndrome with TMA localized to the allograft. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 725A, 2000

De novo hemolytic-uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: role of sirolimus. Transplantation Proceedings 35(5): 1764-1766, 2003

Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. American Journal of Transplantation 6(2): 412-418, 2006

Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome. Clinical Transplantation 11(3): 157-162, 1997

De novo hemolytic uremic syndrome/thrombotic microangiopathy in renal transplanted patients receiving calcineurin inhibitors The role of sirolimus. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 183A, 2002

Hemolytic-uremic syndrome with renal thrombotic microangiopathy. La Revue du Praticien 44(9): 1205-1210, 1994

Thrombomodulin and von Willebrand antigen in thrombotic thrombocytopenia purpura , TTP/hemolytic uremic syndrome , and bone marrow transplant-associated thrombotic microangiopathy. Blood 82(10 Suppl. 1): 151A, 1993

Hemolytic and uremic syndrome in children. Renal thrombotic microangiopathy. Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 75(2): 473-477, 1971

The hemolytic uremic syndrome. Renal cortical thrombotic microangiopathy. Archives of Internal Medicine 126(5): 816-822, 1970

Thrombotic microangiopathy with hypertension and acute renal failure in children (a typical hemolytic uremic syndrome). Journal of Postgraduate Medicine 40(3): 120-122, 1994

Thrombotic microangiopathy thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Orvosi Hetilap 130(33): 1751-1756, 1759, 1989

Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney International 60(3): 831-846, 2001

Thrombotic microangiopathy A proposal for a new terminology for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. JN Journal of Nephrology 8(1): 3-4, 1995

Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy. Transplantation Proceedings 37(4): 1889-1891, 2005

Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient. Seminars in Thrombosis and Hemostasis 25(2): 217-221, 1999